Results 91 to 100 of about 1,674,118 (394)

Hypocomplementemia in systemic sclerosis

Reumatismo, 2011
Hypocomplementemia has been detected in about 15% of unselected series of SSc patients. It constitutes one of the 10 parameters needed to evaluate the European Scleroderma Study Group (EScSG) activity index. A few studies have been so far devoted to investigate the clinical manifestations correlated with this finding.To investigate SSc patients for ...
CUOMO, Giovanna, Abignano G, Ruocco L, VETTORI, Serena, VALENTINI, Gabriele   +4 more
openaire   +5 more sources

Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway

Clinics, 2015
OBJECTIVE: Salvia miltiorrhiza has long been used to treat systemic sclerosis. Tanshinone IIA, one of the phytochemicals derived from the roots of Salvia miltiorrhiza, exhibits multiple biological activities.
Mengguo Liu, Ji Yang, Ming Li
doaj   +1 more source

Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials? [PDF]

, 2010
OBJECTIVES: To obtain an objective, unbiased assessment of skin fibrosis in patients with SSc for use in clinical trials of SSc disease-modifying therapeutics.
Busquets, Joanna, Del Galdo, Francesco, Jimenez, Sergio A., Kissin, Eugene Y.   +3 more
core   +3 more sources

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source

Systemic Sclerosis 2011

International Journal of Rheumatology, 2011
Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by widespread fibrosis affecting the skin, internal organs, and vasculature. However, there are currently no systemic, disease-modifying therapies available for the treatment of the overall condition, and the outcomes remain poor.
Laura K. Hummers, Oliver Distler, Virginia D. Steen, Eswar Krishnan, Lorinda Chung   +4 more
openaire   +3 more sources

Pregnancy in systemic sclerosis [PDF]

Rheumatology, 2008
While in the past, pregnant SSc patients were thought to be at high risk for poor fetal and maternal outcome, at present, careful planning, close monitoring and appropriate therapy allows these patients to have a successful pregnancy. Retrospective studies clearly show an increased frequency of pre-term births and small full-term infants but the ...
Miniati I, Guiducci S, Mecacci F, Mello G, Matucci-Cerinic M   +4 more
openaire   +4 more sources

Aging on Chip: Harnessing the Potential of Microfluidic Technologies in Aging and Rejuvenation Research

Advanced Healthcare Materials, EarlyView.
This review highlights recent advances in microfluidic technologies for modeling human aging and age‐related diseases. It explores how organ‐on‐chip platforms improve physiological relevance, enable rejuvenation strategies, facilitate drug screening, detect senescent cells, and identify biomarkers.
Limor Zwi‐Dantsis, Vignesh Jayarajan, George M. Church, Roger D. Kamm, João Pedro de Magalhães, Emad Moeendarbary   +5 more
wiley   +1 more source

Microphysiological Systems for Comorbidity Studies: Chronic Kidney Disease and Osteoarthritis

Advanced Healthcare Materials, EarlyView.
This review highlights the potential of organ‐on‐a‐chip systems for studying comorbidities, using chronic kidney disease (CKD) and osteoarthritis (OA) as examples. It summarizes recent advances in kidney‐on‐a‐chip and joint‐on‐a‐chip models and discusses their current and potential application in investigating CKD, OA, and CKD‐OA comorbidity, aiming to
Mingying Han, Weiping Lin, Yuanxiong Cao, Patricia Murray, Bettina Wilm, Stephen J McWilliam, Jude Curran, Ruoxiao Xie   +7 more
wiley   +1 more source

Genetics of scleroderma: implications for personalized medicine?

BMC Medicine, 2013
Significant advances have been made in understanding the genetic basis of systemic sclerosis (scleroderma) in recent years. Can these discoveries lead to individualized monitoring and treatment?
Assassi Shervin, Radstake Timothy RDJ, Mayes Maureen D, Martin Javier   +3 more
doaj   +1 more source

Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis. [PDF]

, 2015
Clinical diversity in systemic sclerosis (SSc) reflects multifaceted pathogenesis and the effect of key growth factors or cytokines operating within a disease-specific microenvironment.
Abdi, BA, Abraham, DJ, Clark, KE, Denton, CP, Etomi, O, Guerra, SG, Khan, K, Lopez, H, Martin, GR, Shiwen, X, Stratton, RJ   +10 more
core   +1 more source